Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

17 evidence topics · 11 sources

Summary
  • Blood pressure control: In NHANES data from August 2021 to August 2023, 20.7% of US adults with hypertension had blood pressure controlled to less than 130/80 mm Hg, with no significant change from 2017 to March 2020 (22.2%). In a separate NHANES analysis, the age-adjusted proportion with controlled blood pressure declined from 53.8% in 2013 to 2014 to 43.7% in 2017 to 2018. ICER states that more than 70% of adults with hypertension remain above goal and names clinical inertia, pill burden, additive copays, variable tolerance of side effects, and low awareness as contributors.
  • Underuse of aldosterone-targeted therapy: Among NHANES adults with apparent treatment-resistant hypertension, 8.3% were taking a mineralocorticoid receptor antagonist, rising from 6.3% in 2003 to 2004 to 13.3% in 2017 to 2020. Among US Veterans with apparent treatment-resistant hypertension, 4,277 (1.6%) were tested for primary aldosteronism, and testing was associated with a 4-fold higher likelihood of starting a mineralocorticoid receptor antagonist (hazard ratio 4.10).
  • Tolerability of fourth-line options: The 2025 AHA/ACC guideline states that 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone because of hyperkalemia or antiandrogenic side effects, and that randomized trials have not demonstrated a reduction in home or 24-hour blood pressure with eplerenone at 25 to 100 mg daily compared with placebo. ICER reports gynecomastia rates of 3.9% to 6% with spironolactone in observational hypertension studies. Patient groups told ICER that clinicians are often reluctant to start spironolactone because of potential side effects. With baxdrostat, hyperkalemia led to discontinuation in 5.7% of participants in the BaxHTN long-term extension (safety data to 54 weeks), and serum potassium above 6 mmol/L occurred in 9.5% of the pooled baxdrostat arm and 0.8% of the placebo arm. Edema or fluid retention occurred in 9% of participants receiving aprocitentan at the approved 12.5 mg dose and 2% receiving placebo. ICER describes beta-blockers, alpha blockers, and central sympatholytic drugs as less efficacious and less well tolerated, and the guideline reserves renal denervation for adults with intolerable side effects to optimal drug regimens.
  • Adherence and discontinuation: The weighted national nonadherence rate among 23.8 million adults with hypertension who filled antihypertensive prescriptions was 31.0%. A meta-analysis of 24 studies in apparent treatment-resistant hypertension estimated a pooled nonadherence prevalence of 31.2% (range 3.3% to 86.1%). Among Medicare beneficiaries starting antihypertensive treatment, discontinuation was 21.0% in 2007 and 21.3% in 2012, and low adherence fell from 37.4% in 2007 to 31.7% in 2012.
  • Therapeutic inertia and access: ICER reports hearing that it often takes three to six months to adjust or add a medication in people with uncontrolled hypertension, and patients described readings above 140 mm Hg that were not acted on. The guideline links clinical inertia, among other factors, to the higher frequency of resistant hypertension in Black populations. Patients told ICER that prior authorization and step therapy can lead people to abandon treatment.